Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim
McKesson
Mallinckrodt
Daiichi Sankyo
Chinese Patent Office
US Department of Justice

Generated: May 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

« Back to Dashboard

Clinical Trials for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

Trial ID Title Status Sponsor Phase Summary
NCT00000151 Early Treatment Diabetic Retinopathy Study (ETDRS) Completed National Eye Institute (NEI) Phase 3 To evaluate the effectiveness of both argon laser photocoagulation and aspirin therapy in delaying or preventing progression of early diabetic retinopathy to more severe stages of visual loss and blindness. To help determine the best time to initiate photocoagulation treatment in diabetic retinopathy. To monitor closely the effects of diabetes mellitus and of photocoagulation on visual function. To produce natural history data that can be used to identify risk factors and test etiologic hypotheses in diabetic retinopathy.
NCT00000152 Randomized Trial of Beta-Carotene and Macular Degeneration Unknown status National Eye Institute (NEI) Phase 3 To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
NCT00000157 Randomized Trial of Aspirin and Cataracts in U.S. Physicians Terminated National Eye Institute (NEI) Phase 3 To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.
NCT00000161 Randomized Trials of Vitamin Supplements and Eye Disease Unknown status National Eye Institute (NEI) Phase 3 To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

Condition Name

Condition Name for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Intervention Trials
Migraine 197
Coronary Artery Disease 127
Migraine Disorders 62
Acute Coronary Syndrome 59
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Intervention Trials
Migraine Disorders 414
Coronary Artery Disease 188
Myocardial Ischemia 180
Coronary Disease 169
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

Trials by Country

Trials by Country for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Location Trials
Japan 317
Australia 95
France 94
Netherlands 71
Denmark 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Location Trials
New York 198
California 185
Texas 181
Florida 174
Pennsylvania 157
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

Clinical Trial Phase

Clinical Trial Phase for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Clinical Trial Phase Trials
Phase 4 454
Phase 3 397
Phase 2/Phase 3 59
[disabled in preview] 250
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Clinical Trial Phase Trials
Completed 812
Recruiting 260
Unknown status 157
[disabled in preview] 125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

Sponsor Name

Sponsor Name for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Sponsor Trials
Merck Sharp & Dohme Corp. 56
GlaxoSmithKline 46
AstraZeneca 46
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Sponsor Trials
Other 1568
Industry 744
NIH 133
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
McKesson
Fuji
Cantor Fitzgerald
UBS
Julphar
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.